Press releases
- Press releases
- Browse
Press releases
With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy. Pharmalicensing has revised and updated its successful Early Stage report More
London, England ReGen Therapeutics Plc. ('ReGen'), announces that it has today entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. More
BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jun 2006 - 1068 pages - $2,495
Feb 2011 - 209 pages - $3,500
Oct 2010 - 53 pages - $1,000
Feb 2011 - 75 pages - $1,000
Nov 2007 - 173 pages - $1,860
Jan 2008 - 55 pages - $495
Apr 2008 - 250 pages - $3,995
Dec 2007 - 49 pages - $495
Jun 2011 - 132 pages - $2,350
Jan 2010 - $75
Your selection
Browse By
- Industry sector
- Bioinformatics
- Combinatorial biology
- Combinatorial chemistry
- Drug research platforms
- Genomics
- High throughput screening
- Proteomics
- Therapeutic target
- Age-related disorders (other)
- Amyotrophic lateral sclerosis
- CNS (other)
- Neurodegenerative disorders
- Neurological
- Pain
- Psychiatric
- Subarachnoid hemorrhage
- Traumatic brain injury
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us